• Willow’s plan to provide biosynthetic cannabinoid has potential to disrupt the cannabis-industry supply chain
• Biosynthetically derived cannabinoids offer unique advantages related to reliability, scalability, quality and cost
• Key collaboration allows company to capitalize on enormous market opportunity

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF), an emerging biotechnology company focused on the biosynthetic production of cannabinoids, believes that the cannabis industry presents an exciting opportunity for the well-positioned company. As the market anticipates the legalization of cannabis-derivative products in Canada, and the CBD legal landscape continues to change rapidly in the United States and around the world, cannabinoids are appearing as a key ingredient in a broad range of products, from health and wellness and pet care options to beverages and edibles. Willow’s ability to provide biosynthetic cannabinoids to this exploding market has the potential to disrupt the traditional cannabis industry supply chain.

Biosynthetically derived cannabinoids offer unique advantages related to reliability, scalability, quality, and cost. As an expert in the field of synthetic biology, Willow is focusing on developing pure, pharmaceutical-grade product that consistently provides these benefits for its customers. Willow’s processes offer many advantages over extraction from plants, including the possibility of improving the performance of some cannabinoids over their naturally derived versions.

As part of the company’s savvy strategy to become a leader in the pure-cannabinoid manufacturing space, Willow entered into a joint development agreement with Noramco, the number one supplier of controlled substances in the United States, earlier this year (http://ibn.fm/HEemD). This collaboration provides a symbiotic way for both companies to capitalize on an enormous market opportunity.

Noramco will benefit from Willow’s expertise in developing active pharmaceutical ingredients in yeast while Willow will benefit from Noramco’s manufacturing and distribution channels. In addition, thanks to Noramco’s extensive experience in dealing with various regulatory bodies, WLLW could save a significant amount of time and resources associated with regulatory submissions. Finally, Willow can leverage Noramco’s supply-chain expertise in selling synthetic CBD. Noramco currently supplies products to over 30 countries and is a supplier of chemically synthesized cannabinoids to pharmaceutical companies.

The market outlook for biosynthetic cannabinoid products is extremely promising. Cowen estimates that by 2025, the United States CBD market could reach $16 billion (http://ibn.fm/DgxEe). Additionally, Ackrell Capital estimates that the pharmaceutical market for cannabinoids will reach $50 billion by 2029 (http://ibn.fm/gv9Vt). With the goal of being one of the first companies providing biosynthetic alternatives in this space, Willow sees a tremendous opportunity to grab a sizeable market share in a fast-growing global market.

This is especially true on the pharma front where the list of trials and indications continues to grow rapidly. Approximately 40 CBD and other cannabinoid-based treatment options are currently in clinical trials for indications such as post-traumatic stress disorder, epilepsy, Parkinson’s disease, chronic pain, schizophrenia and others (http://ibn.fm/fiLac). Applications for pharmaceutical-grade cannabinoids is expected to continue to expand.

If only a handful of those clinical trials become successful, WLLW expects to see market size for cannabinoids increase substantially, providing Willow will have a significant opportunity to supply biosynthetically derived cannabinoids to various pharmaceutical companies for use in pre-clinical and eventually clinical trials.

Willow ultimately intends to biosynthetically produce a variety of cannabinoids using biosynthesis, but its first target molecule will be CBD. The company has a fully integrated leadership team based out of Canada and the United States to handle all stages of the upstream cannabinoid development cycle. Additionally, by having two labs in Canada, where cannabis is Federally legal, Willow is able to access and work with the cannabis plant to allow its team to make significant discoveries outside of what is known today. This is a key advantage for the company. Willow is fully funded to achieve commercialization of CBD with its partner Noramco.

For more information, visit the company’s website at www.WillowBio.com

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW

• Wholly owned subsidiary Semcon IP Inc. resolves all claims and disputes by and between Semcon IP Inc. and AsusTek Computer Inc. relating to Semcon’s Power Management Portfolio
• Semcon’s licensing program has seen significant activity in 2019 with additional cases pending
• Trading on the OTCQB and with patent licensing revenues for the nine-months ended September 30, 2019, of approximately $2 million, QPRC offers investors an exciting opportunity to participate in the IP monetization space

The Power Management/Bus Controller Portfolio, acquired by company Quest Patent Research Corp. (OTCQB: QPRC) from Intellectual Ventures in October 2015 and transferred to wholly owned subsidiary, Semcon IP Inc., consists of four United States patents that cover fundamental technology for adjusting the processor clock and voltage to save power based on the operating characteristics of the processor and one United States patent that relates to coordinating direct bus communications between subsystems in an assigned channel.

In May 2018, Semcon brought a patent infringement action in the United States District Court for the Eastern District of Texas against AsusTeK Computer Inc. for infringement of certain of the Power Management Portfolio, alleging that “Asus has infringed and is continuing to infringe the Patents-in-Suit by making, using, selling, offering to sell, and/or importing, and by actively inducing others to make, use, sell, offer to sell and/or importing, products that utilize SoCs and associated software that perform DCVS or DVFS for power management, including Qualcomm Snapdragon SoCs including at least the Snapdragon 800, 820 and 821 SoCs. Such Asus products include at least the Zenfone 3 Ultra, Zenfone 3 Deluxe, Zenfone AR, Zenpad 3 and Padfone X smartphones and tablets. Additionally, these Asus products include software that utilizes DCVS and/or DVFS for power management.” A copy of the complaint is available at  http://ibn.fm/eAq6o.

In July 2019, Asus moved for summary judgement of non-infringement, only to withdraw their motion in late August. A copy of the motion is available at http://ibn.fm/adlA2, and Semcon’s response is available at http://ibn.fm/mCY79. In September 2019, Asus moved for leave to serve amended initial disclosures and to produce discovery out of time. A copy of the motion is available at http://ibn.fm/cD2ME, and Semcon’s response is available at http://ibn.fm/HAfhC.

A Pretrial Conference was held on October 28, 2019, during which the court gave the parties instructions for jury selection, set trial for December 9th, heard oral arguments on the motion to leave, denied the motion and ordered the parties to return to mediation. The minutes from the pretrial conference are available at http://ibn.fm/p4uwd.

The Supplemental Mediators Report, filed with the court on November 18, 2019, states “a settlement has been reached as to all claims by and between Plaintiff Semcon IP, Inc. and Defendant AsusTek Computer Inc. This case is now settled.” A copy of the mediator’s report is available at http://ibn.fm/k97QB.

Semcon’s licensing program has seen substantial activity of late having recently resolved cases against Capri Holdings Limited (f/k/a/ Michael Kors Holdings Limited), Kyocera Corporation and Amazon.com, Inc. Semcon has additional cases pending against Louis Vuitton North America, Inc. (TXED-2-19-cv-00122); TCT Mobile International Limited et al (TXED-2-18-cv-00194); and Shenzhen OnePlus Science & Technology Co., Ltd. (TXED-2-18-cv-00196).

Revenues for the period ended September 30, 2019, which were approximately $2 million according to the Company’s most recent quarterly report (available at http://ibn.fm/qVQZ9). Annual revenues have grown from around $200,000 in 2015 to approximately $7 million in 2018. Quest trades on the OTCQB.

For more information, visit the company’s website at www.QPRC.com

NOTE TO INVESTORS: The latest news and updates relating to QPRC are available in the company’s newsroom at  http://ibn.fm/QPRC

• CIIX anticipates launch of hemp-infused wrinkle cream in China
• Through subsidiary CBD Biotech, CIIX will focus hemp and CBD products on the blooming Chinese market
• The company noted impressive sales, revenue growth for Q1 2020, greatly due to success of CBD Biotech

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang noted the enormous potential for cosmetics infused with industrial hemp in a RedChip Money Report interview. This sentiment was echoed in his letter to shareholders, where he noted that CBD-infused cosmetics will the company and its subsidiary, CBD Biotech, to a Chinese market of 1.4 billion people. CIIX plans to launch industrial hemp-infused wrinkle cream cosmetics to this market in the near future (http://ibn.fm/4G7xU).

In the interview, Wang outlined the company’s historic presence in China’s’s burgeoning CBD-industry. As the first company to enter the Chinese CBD products market, the move represents tremendous opportunity for CIIX’s CBD division, he said. Additionally, the company has been marketing its CBD products to Chinese-speaking American consumers since it entered the industry in 2017. Wang referenced the incredible market potential of the more than 3.5 million Chinese consumers in the United States, to which CIIX already markets gummies, CBD oil, and CBD-infused cosmetics (http://ibn.fm/EQcsr).

Looking forward, Wang described the company’s intent to diversify its revenue streams in FY2020, planning to focus on its core investor relations business as well as continuing to expand and market its industrial hemp-infused/CBD products in China and the United States. This strategy shows potential for greater revenues and profits, as “the buying power from the Chinese consumer will be huge,” he said.

“While cannabis use in China is illegal, cannabis-based oils including industrial hemp extract may be added to cosmetics, thus opening a potential market of nearly 1.4 billion people for the company,” Wang noted. “As we analyze the legality/trends in other Asian countries, we have an advantage with ‘feet on the ground’ in that part of the world.”

CIIX will also focus in 2020 on its core business of investor relations. It already owns a minority interest in a U.S.-based investment bank, Donald Capital, LLC and is in the process of establishing a “working cooperation” with a private equity firm in China. Wang said, “Both of these relationships are projected to be a source of recurring revenue for years to come.”

This continued emphasis on its CBD arm has led CIIX to impressive revenue reporting. CIIX reported in its 8K filing to the SEC sharply higher revenues for Q1 2020, the three months ended August 31, 2019. Sales jumped to $1,956,960, 174.7% higher than the $712,360 for the same quarter the prior year. Hemp and CBD product revenues drove that increase with a contribution of $948,751 for the 2020 quarter, a 569.2% rise from the $141,764 in Q1 2019 (http://ibn.fm/nArjp).

Additionally, CIIX’s core investor relations business generated $821,361 in Q1 2020, a 200% improvement over the $271,248 the same period the prior year. CIIX has refocused and grown its core business (http://ibn.fm/cltnt).

With an eye toward profitability, CIIX is streamlining its operations and maximizing current resources across the board. As it refocuses on its core investor relations business and diversifies and grows its industrial hemp/infused products in China and the U.S., Wang is optimistic. Wang said, “Although we still have work to do in this regard, with these objectives in mind, with a dedicated and experienced management team, and most importantly, the continued support of our loyal shareholders, we look forward to a healthy FY2020.”

CIIX offers its audience of Chinese-speaking investors real time market commentary, analysis and educational-related services in Chinese character language sets. When asked why investors should put their trust in CIIX, Wang said, “We have been around for 20 years. We put our roots into the United States of America, so I believe people can trust us. We are right here, right now, and local.” CIIX offers investors an inexpensive stock option poised on the brink of tremendous market opportunity in China’s growing CBD-infused cosmetic industry.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• An estimated 20% of wastewater is treated globally, with much lower percentage being recycled
• OriginClear addresses situation by providing water-treatment and conveyance products that are installed on site
• CEO has goal for company to be driving force to take water industry from $1 trillion to a $5 trillion market

In a world where an estimated 20% of wastewater globally is treated and a much lower percentage is recycled (http://ibn.fm/IGQZW), OriginClear Inc. (OTC: OCLND) may be key to the solution. A leading provider of water-treatment solutions, OriginClear is uniquely prepared to offer organizations of all types – hotels and resorts, real-estate housing developments, office buildings, military installations, schools, farms, food and beverage manufacturers, industrial warehouses, oil and gas producers, medical and pharmaceutical facilities and more – the tools and services to treat and recycle their own water.

In a recent Grit Daily article (http://ibn.fm/aHErZ), the author noted that OCLN CEO Riggs Eckelberry is “driving the disruption of a trillion-dollar industry that has fallen behind the times and is affecting the health of millions. That industry is Big Water.” Billion-dollar centralized water systems aren’t coping with demand, the article reported, and water quality is steadily getting worse. Eckelberry “has a goal for his company, OriginClear, to be the driving force to take the water industry from $1 trillion to a $5 trillion dollar market.”

The trillion-dollar number comes from a “Water Online” report, which states that “a water scarcity ‘perfect storm’ is approaching, and that makes it a good time to invest in water reuse technologies. Analysts at Bank of America Merrill Lynch Global Research said in a new report. ‘For investors, increased demand for water could generate potent investment opportunities. Water-related industries already represent a roughly $500 billion market,’ the report said, citing Sarbjit Nahal, an equity strategist at BofA Merrill Lynch Global Research. ‘We think it will double to $1 trillion by 2020,’ he said” (http://ibn.fm/xClqg).

Eckleberry explains how OriginClear believes that $1 trillion estimate can increase to $5 trillion by noting that, based on a UN World Water Development report (http://ibn.fm/KSml2), over 80% of all wastewater is discharged without treatment. “If only 20% of the water is treated,” Eckleberry noted in a recent CEO update (http://ibn.fm/YD1jD), “this one-trillion dollar industry should be a five-trillion dollar industry.”

OriginClear plans to build this industry by providing professional-grade, water-treatment and conveyance products that are installed onsite at commercial and industrial properties. The company is leading a new generation of water companies that are committed to serving businesses looking for compact, advanced technologies at the point of use, with modular systems that are shipped to the site and dropped in place.

The benefit of these systems is vast. Once installed, OriginClear water-treatment solutions boost a client’s real-estate asset value as a fundamental capital improvement, provide long-lasting water savings, create self-sufficiency by providing water ownership, offer control over water quality, increase productivity and reduce environmental, health and safety risks from pollution, contamination and corrosion.

OriginClear offers breakthrough water-treatment and conveyance products that effectively improve the quality of water by returning it to its original and clear condition. OCLN’s stated mission is to empower this global movement with products that enable water independence and help make clean water available for all. The company provide modular water-purification systems, storage systems, pump stations, wastewater systems and control systems.

For more information, visit the company’s website at www.OriginClear.com

NOTE TO INVESTORS: The latest news and updates relating to OCLN are available in the company’s newsroom at http://ibn.fm/OCLN

• InsuraGuest’s guest protection policy, extended to each guest at check-in, covers accident damages, loss, and accidental medical
• The InsuraGuest™ InsurTech platform can integrate with 70 hotel and vacation rental property management systems
• Number of vacation rental users expected to top 297 million worldwide in 2019

Service-as-a-software (SaaS) company InsuraGuest Inc. has entered the rapidly growing vacation rental market with its proprietary software platform offering specialized insurance coverage to all guests from check-in to check-out. InsuraGuest’s innovative InsurTech platform protects guests during their stay at vacation rental properties in an industry that is expected to host more than 297 million total vacation rental users worldwide in 2019 (http://ibn.fm/CMnjv).

Additionally, projected vacation-rental industry revenue for 2019 stands at $57.669 billion with a market growth rate of 6.9 percent. Statistics indicate that U.S. travel to overseas markets totaled 35.1 million, up by 7 percent, and that almost 25 percent of Americans report engaging with short-term rental platforms – a massive increase to of 277 percent from the previous 6 percent engagement rate.

InsuraGuest is positioned to tap into the opportunities presented by this fast-growing market by offering a product that fills an existing gap in travelers’ insurance. Conventional insurance fails to adequately cover the full scope of risks that travelers and hotel or property owners face. In cases where an incidence of damage or an accident cannot be attributed to the property directly, the guest may have no claim to coverage at all. Thus, InsuraGuest becomes the first line of defense for both the guest and the property, by providing specific coverage for issues such as accidental damage to rooms, lost or stolen items, medical expenses, and death or dismemberment.

Adoption of the technology is also made easy by the InsuraGuest™ InsurTech platform’s capability to integrate with more than 70 hotel and vacation rental property management systems worldwide. With that in mind, InsuraGuest is already working to expand the scope of its platform and products into the European Union, the United Kingdom, and Asia by the middle of next year.

Currently, the U.S. accounts for 20% of all vacation rental properties, Europe accounts for 60%, and the rest of the world accounts for 20%. Europe in general is an impressive hospitality stay market that’s twice the size of the U.S. market: according to InsuraGuest CEO Douglas Anderson, there were 2.8 billion hotel nights stayed in Europe, compared to approximately 1.1 billion in the U.S. in 2018.

InsuraGuest has already signed a letter of intent with a licensed Master General Agent operating in EU and U.K. markets, which will allow the company to distribute its products and proprietary platform to the hotel and vacation rental markets in these regions. Now offering coverage on the U.S. market coast-to-coast, expansion into Europe will also give InsuraGuest access to a combined demographic of 3.9 billion hotel nights stayed and significantly increase its opportunities for growth on the vacation rental markets in these regions.

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to InsuraGuest are available in the company’s newsroom at http://ibn.fm/InsuraGuest

• Most significant patent filed is also the most comprehensive, covering broad areas of cannabinoid polymeric nanoparticles and fibers
• Company is committed to continuing research program and expand its intellectual property portfolio over the coming months
• MCTC participating in multiple growing verticals within global cannabis industry through acquisitions, strategic partnerships, and intellectual property

MCTC Holdings Inc. (OTC: MCTC), a cannabinoid science innovator focused on high-growth and high-margins sub-sectors of the cannabis and hemp industry, filed its fourth cannabinoid delivery technology patent. The patent broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium, the company announced in a press release (http://ibn.fm/bCTyI).

MCTC’s R&D program continues with research into development of improved methods to give living systems access to cannabinoids. A key component of the research program is the development of novel polymeric nanofibers and nanoparticles, which have very high potential to significantly improve bioavailability, while allowing for tunability of cannabinoid combinations, ultra-high loading rates, precise dosing, and controlled release parameters at the same time.

According to CEO Arman Tabatabaei, this is the most significant patent the company has filed. “It is by far the most comprehensive covering broad areas of cannabinoid polymeric nanoparticles and fibers. The claims not only cover a plurality of particles within at least a partially water-soluble carrier, but also the process utilizing the precursor mixtures. Not only are nanoparticles and nanofibers included, but also particles below 1.5 microns,” Tabatabaei explained.

The company filed three other patents related to cannabinoid delivery systems in recent months. The first patent, which was on an edible dissolvable film for the delivery of cannabinoids, was the product of collaboration between MCTC and Cannabis Nanosciences, Inc. The companies also cooperated on the second patent, filed on cannabinoid nanoparticles combining TPGS, a water-soluble form of vitamin E. TPGS is a proven and safe bioenhancer of cannabinoids and other hydrophobic compounds. MCTC’s third patent was for a unique 3D printed, 4-dimensional, shape-changing cannabinoid delivery system for beverages.

“We expect to continue to expand our intellectual property portfolio over the coming weeks and months as our research and development programs continue. We believe the area of cannabinoid delivery systems is one of the most exciting areas of the growing cannabinoid sciences arena,” Tabatabaei added.

Currently pending a name change to Cannabis Global, Inc., MCTC Holdings is an integrated cannabis business operation focused on multiple verticals within the fast-growing cannabis and hemp industries via acquisitions, partnerships and intellectual property. An innovator in the field of cannabinoid nanoparticles and infusion technologies, the company concentrates its efforts on the middle part of the industry’s value chain, characterized by high margins and high growth. Its advanced cannabinoid delivery system research can revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and transdermal applications, with the potential for exponential growth in the industry.

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

• Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-op
• SofPulse (R) use causes 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication and 50% less inflammation
• Bioelectric medicine is a $17 billion market, projected to exceed $33 billion annually by 2025

Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc.’s (OTCQB: ENDV) proprietary SofPulse(R) technology is being successfully used by surgeons at New Hanover Regional Medical Center (NHRMC) in North Carolina to reduce the volume of opioid prescriptions and remove the need for patients to take narcotics for pain after surgery.

According to a WECT.com report, NHRMC has been using SofPulse(R) for six months, during which medical staff noticed a 30-40 percent drop in post-op narcotic prescriptions (http://ibn.fm/KQSDf). The report quoted urologist Dr. Roc McCarthy as detailing several benefits of the technology, including faster recovery times and fewer people asking for pain medication.

The non-invasive SofPulse(R) device uses electromagnetic waves to reduce inflammation after surgery. It is the flagship product of Endonovo Therapeutics and its proprietary Electroceutical(R) Therapy, developed for the treatment of inflammation, cardiovascular disease, and central nervous system disorders such as traumatic brain injury (TBI), acute concussions, post-concussion syndrome, and multiple sclerosis.

According to McCarthy, many patients are receptive to the SofPulse(R) device and opt to use it instead of pain medication because they are worried about the side effects of opioids, including addiction risks in the context of the national opioid crisis. The opioid crisis has reached a peak in the country, putting intense pressure on pharmaceutical companies, health care providers, and medical facilities to reduce the use of painkillers. This has created demand for other viable pain control solutions, which were quite limited until recently.

While the technology behind SofPulse(R) isn’t new, it has not been fully developed until now, McCarthy added. “It’s just opening the door to a world of opportunity for people to come up and innovate other ways of decreasing the amount of pain that people are having,” he said.

SofPulse(R) has prospects to reduce the need and intake of prescription drugs over the long term. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. This is a positive development in light of 2010 data of the Department of Health and Human Services, according to which 31% of adverse events and 42% of temporary harm events among Medicare patients in acute care hospitals were related to medication.

According to Endonovo data, the technology leads to a 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication, and 50% less inflammation. SofPulse(R) works by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for recovery to occur (http://ibn.fm/JkQNY).

Endonovo’s Electroceutical(R) Therapy is certified for the treatment of chronic wounds by the Centers for Medicare and Medicaid Services (CMS) nationwide. The success of this proprietary device is rapidly broadening the company’s horizons, providing them with new and unique opportunities to enter the buoyant bioelectric medicine market, which is currently worth $17 billion and projected to exceed $33.14 billion annually by 2025 (http://ibn.fm/AZEdK).

Endonovo developed its SofPulse(R) technology in collaboration with researchers and medical centers. The wearable, non-invasive pain reducer continues to undergo testing as a way of limiting opioid use with emphasis on post-surgical pain relief and recovery. These technological developments represent massive, long-term valuation potential for the company.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Former Head of Digital Commerce at HSN, Jill Braff brings a wealth of experience in marketing, e-commerce to her new role
• CEO believes PLUS online CBD business will be transformative for the company
• Braff deems PLUS one of most promising companies in a high-growth industry

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), a leading cannabis-branded product company with the two best-selling cannabis products in California, recently announced the appointment of ecommerce senior executive Jill Braff to the company’s board of directors (http://ibn.fm/8hJSE). The move is aimed at further strengthening the company’s already impressive digital sales and marketing expertise.

“We couldn’t be more thrilled that Jill has agreed to join the PLUS family as the fifth member of our board of directors,” PLUS co-founder and CEO Jake Heimark stated in a news release. “Her experience in both digital and traditional marketing makes her the perfect fit as we continue to grow our online CBD business, a distribution channel that we believe will be transformative for the PLUS brand. I look forward to leaning on her insight and invaluable experience as we navigate the rapidly evolving world of direct-to-consumer sales and marketing.”

Currently serving as president of Brit + Co, Braff brings a wealth of experience in marketing and e-commerce to this new responsibility. Braff has shouldered senior executive roles at a number of well-known companies including HSN, where she was executive vice president over digital commerce; Ellen (DeGeneres) Digital Ventures, where she was general manager; and Ancestry.com, where she was vice president of marketing.

“The opportunity to join PLUS, one of the most promising companies in a high-growth industry like cannabis, is extremely exciting,” Braff added. “I’m a fan of early market leaders. The deliberate and focused approach PLUS has taken to building a branded-products company drew me to this opportunity, and I look forward to playing a key role in advancing the company’s strategy forward.”

In her previous roles, Braff received numerous honors and awards, including being recognized as one of the Top Women in Digital by Cynopsis Media and one of the 40 Most Influential People under 40 by Silicon Valley Business Journal.

Braff joins PLUS at a pivotal point in time. The Plus Products’ cannabis-infused edibles are now available in more than 360 licensed retailers across the state of California, and the company recently launched its products in Nevada, one of the nation’s most promising cannabis markets. In addition, PLUS has unveiled a line of 100% hemp-CBD-infused gummies, available on its website (http://ibn.fm/Zs0Xi). The company’s mission is to make cannabis safe and approachable, which begins with high-quality products that deliver consistent consumer experiences.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• Predictive Oncology subsidiary TumorGenesis developing new PDx models needed to understand the complexities of cancer
• Tremendous unmet need for patient-derived tumors (PDx) for new drug development – current mouse models unreliable
• TumorGenesis unique in the industry; its ovarian-cancer cells haven’t been widely available like most other PDx samples
• Multi-billion-dollar market opportunity

As the precision-medicine industry continues to integrate technology to improve the efficiency and efficacy of its strategies, clinicians are realizing the need for actual patient samples to determine the best methods to defeat cancer. Researchers are now turning to patient-derived tumors (PDx) to better understand the complexities and vagaries of the disease which has become the new focus in cancer research. Predictive Oncology Inc. (NASDAQ: POAI) is executing on its mission to deliver cutting-edge services for the oncology research and profiling market. The company’s subsidiary, TumorGenesis, was formed in 2018 with a mission to create reliable, reproducible and translatable cancer cell capture, culture and screening using lab-ready to use technologies.

TumorGenesis will build kits used in cancer research laboratories around the world. Kits, media and cells are valued today at $2.8 billion growing at CAGR 12.9% to $6.8 billion by 2025.Predictive Oncology believes TumorGenesis’ novel PDx platform will provide pharmaceutical and biotech companies the tools needed to identify, understand and attack tumors. Through the work of TumorGenesis on PDx profiles, Predictive Oncology intends to become an important conduit for rapid drug identification, development and approvals – objectives worth billions in the space.

PDx models have proved to be a critical component of early cancer detection and the global research community has focused efforts on mastering the complexities of cancer and moving rapidly to PDx models to do so. There’s now a major emphasis in cancer research to learn more about cancer’s origins and find ways to identify early that cancer is present and then prevent or treat cancer cells and cancer cell colonies in their infancy, long before overt symptoms of cancer reveal themselves. Certain cancers like ovarian, pancreatic and brain cancers as well as many others, are highly metastatic, have little if any treatment options and little reliable way of early detection.

However, to study cancer cells, they must be isolated and perpetuated: in short, immortalized. Unfortunately, this process created more aberrations of the genetics of the isolated cancer cells. The isolation or “immortalization” of these cancer cell lines also created what researchers call homogeneous cancer colonies, meaning the cancer cells all behaved the same way.

Tumors are not homogeneous but are heterogeneous and other researchers have found that the homogeneous cell lines are also admixed with clonal variants that can rapidly mutate even further, confounding research. Tumors and cancer cells are much more complex than originally perceived.

Everyone in the cancer research community has now focused efforts on mastering the culturing of cancer cells and preserving their in vivo (in patient) characteristics. The goal is to successfully grow in the laboratory and subsequently implanted in mice or rats (PDx Mouse and PDx Rat), a tumor that accurately represents the patient’s tumor. TumorGenesis is rapidly developing its technology in this multibillion-dollar industry of Patient Derived Tumors (PDx), the focus of all pharmaceutical, biotech, government and independent research institutes around the world.

TumorGenesis currently has 25 ovarian-cancer cell types that have been validated utilizing PDx samples. The company’s program includes plans to isolate these ovarian-cancer cell types and study their response to drugs, which is unique in the industry as these ovarian-cancer cells haven’t been widely available like almost all other PDx samples. This gives POAI, via TumorGenesis, a striking competitive advantage which can be measured both qualitatively and quantitatively. Using its unique PDx samples then screening drugs and drug combinations against its extensive library of ovarian-cancer cell types, TumorGenesis is building the kits that are desperately needed facilitate the development of new, more effective drugs that are created in response real human cancer cells. Through its utilization of PDx models, TumorGenesis’ work has synergistically supported Predictive Oncology’s quest to deliver the necessary tools to defeat ovarian cancer first then move to all other cancer sub-types. This is Predictive Oncology’s overarching strategy, delineated in its CancerQuest2020 initiative.

Predictive Oncology is a data and AI-driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients. POAI is at the vanguard of the latest scientific endeavors in cancer research: to better understand the complexities of individual cancers and tailor individualized therapeutic protocols. In addition to providing the molecular information necessary to help deliver on the promise of personalized medicine, the comprehensive molecular information delivered by Predictive Oncology is of enormous value to Pharma in new drug development and the PDx models developed by TumorGenesis may provide the pathways for Pharma to find successful solutions to the scourge of cancer.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Wholly owned subsidiary Mariner IC Inc. completes another successful licensing campaign around its Anchor Structure Portfolio
• Patent Licensing Revenues for the nine-months ended September 30, 2019 were approximately $2 million
• The company remains active in monetizing its existing portfolio as well as evaluating potential acquisitions
• QPRC trades on the OTCQB, offering investors an exciting opportunity to participate in the IP monetization space

The Anchor Structure Portfolio, acquired by company Quest Patent Research Corp. (OTCQB: QPRC) from Intellectual Ventures in October 2015 and transferred to wholly owned subsidiary, Mariner IC Inc., consists of two United States patents which relate to technology for incorporating metal structures in the corners and edges of semiconductor dies to prevent cracking from stresses.

Following the execution of funding agreements and the engagement of counsel, in 2016, Mariner IC brought patent infringement suits in the United States District Court for the Eastern District of Texas against MediaTek Inc., Texas Instruments Incorporated, LG Electronics Inc., Toshiba Corporation. Those cases were resolved in 2017, generating licensing fees of approximately $1.2 million.

In 2018, Mariner IC brought patent infringement suits in the United States District Court for the Eastern District of Texas against Sharp Corporation, AsusTek Computer Inc., TiVo Corporation and Huawei Device Co., Ltd et. al. As of September 30, 2019, the action against Huawei is currently stayed pending settlement and the actions against TiVo, AsusTek and Sharp were dismissed. Revenues for the period ended September 30, 2019, which were approximately $2 million according to the Company’s most recent quarterly report (http://ibn.fm/3gvxA), includes the revenue from these cases.

“IP monetization poses significant risks. Not only do you have to prove infringement, but a defendant can raise up to 27 patent defenses, any one of which can be case dispositive if successful. Our assets have to survive quite a gauntlet. The success of the Mariner campaigns certainly demonstrates management’s ability to identify, acquire and monetize valuable intellectual property,” Quest CEO Jon Scahill stated in a news release. “IP monetization is complex, costly and takes time to realize. We constantly evaluate ways to mitigate risk, reduce cost and accelerate the timing of our licensing efforts. Management has a clear vision for building long-term value centered around monetizing our existing portfolio as well as continuing to expand our portfolio of valuable IP. The objective is to replicate, many times over, the success shown by the Mariner campaigns.”

The Company has been extremely active in harvesting its existing portfolio of IP assets. Through the end of the third quarter, Quest has partially or fully resolved 8 cases with an additional 7 cases successfully stayed pending settlement.

Quest announced its listing on the OTCQB index in May as part of its growth efforts and plans to continually build financing and revenue sources (http://ibn.fm/ItqLX). The company’s annual revenues have grown from around $200,000 in 2015 to $7 million in patent licensing fees last year.

For more information, visit the company’s website at www.QPRC.com

NOTE TO INVESTORS: The latest news and updates relating to QPRC are available in the company’s newsroom at http://ibn.fm/QPRC